| Literature DB >> 35237589 |
Sunday Bulus Peter1, Zhina Qiao1, Hero Nmeri Godspower1, Samaila Boyi Ajeje1, Meijuan Xu1, Xian Zhang1, Taowei Yang1, Zhiming Rao1.
Abstract
Lactic acid bacteria represent a worthwhile organism within the microbial consortium for the food sector, health, and biotechnological applications. They tend to offer high stability to environmental conditions, with an indicated increase in product yield, alongside their moderate antimicrobial activity. Lack of endotoxins and inclusion bodies, extracellular secretion, and surface display with other unique properties, are all winning attributes of these Gram-positive lactic acid bacteria, of which, Pediococcus is progressively becoming an attractive and promising host, as the next-generation probiotic comparable with other well-known model systems. Here, we presented the biotechnological developments in Pediococcal bacteriocin expression system, contemporary variegated models of Pediococcus and lactic acid bacteria strains as microbial cell factory, most recent applications as possible live delivery vector for use as therapeutics, as well as upsurging challenges and future perspective. With the radical introduction of artificial intelligence and neural network in Synthetic Biology, the microbial usage of lactic acid bacteria as an alternative eco-friendly strain, with safe use properties compared with the already known conventional strains is expected to see an increase in various food and biotechnological applications in years to come as it offers better hope of safety, accuracy, and higher efficiency.Entities:
Keywords: Pediococcus; bacteriocin; biotherapeutics; deep neural network; genome editing; probiotics
Year: 2022 PMID: 35237589 PMCID: PMC8883390 DOI: 10.3389/fbioe.2021.802031
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 1Possible Products in the Natural Metabolic Pathways of LAB and Pediococci under Various Conditions. The dashed arrows indicate different enzymatic steps. Black: taste, texture, medicinal ingredients and health uses; Green: chemicals and fuels. F 6-P, fructose 6-phosphate; DHAP, dihydroxyacetone phosphate; Fructose 1,6BiP, fructose 1,6 bisphosphate; PEP, phosphoenolpyruvate; G 6-P, Glucose-6-Phosphate.
Plasmid and genome-based protein expression system in LAB.
| Organism | Vector expression system | Description | References |
|---|---|---|---|
| Plasmid-encoded System | |||
|
| Pzn zitR and Zirex |
| (D. and I., 2004; |
| P170 | At low pH, the |
| |
| PxylT | Xylose induced; promoter, P |
| |
| SICE | Stress induced |
| |
| ACE | Agmatine induced; having |
| |
| NICE | Nisin induced; based on a two-component signal transduction |
| |
| Genome-encoded System | |||
|
| pSA3-based suicide vector (pTRK327) | A non-repetitive vector with sequences homologous to the insertion site |
|
|
| pTNI with thermosensitive replicon | Site-specific replacement of chromosomal DNA sequence |
|
|
| pSEUDO vector | Stable genetic insertion in a pre-set transcriptionally inert part of genome |
|
|
| |||
FIGURE 2Genomic Approaches and Antioxidative System of Lactic Acid Bacteria (LAB): (A) Genome-based approaches to the characterization of promising probiotic strains. (B) Antioxidative system of LAB; Thiols, Antioxidant enzymes and Respiratory repertoire which allows them to withstand various environmental stresses that generates highly reactive species or through the NOX (NADH oxidase) like H2O2. ROS, Reactive oxygen species; SOD, Superoxide dismutase; GSH, Glutathione; TRX, Thioredoxin-thioredoxin reductase system; CAT, catalase.
New genome engineering possibility with recombineering and CRISPR–Cas system in LAB.
| Organism | Vector/system | Characteristics | References |
|---|---|---|---|
|
| pLABTarget | For introducing sgRNA sequence to target specific genetic loci |
|
|
| pNZCRISPR (a single plasmid inducible CRISPR-Cas 9 system) | To drive Cas9 expression and transcription of two nisin promoters, respectively |
|
|
| CRISPR-Cas system + (ss)DNA recombineering (RecT-assisted CRISPR–Cas9 system) | Enhances performance in bacteria with low recombineering efficiency; Cas 9 directed toward eliminating unmodified bacterial strains (codon saturation mutagenesis and gene deletions) (100% efficiency) |
|
|
| pLCNICK A CRISPR–Cas9D10A-based plasmid | Replaces wild-type Cas 9 with Cas 9N10A (nickase), increasing efficiency (25%–65%) |
|
|
| a RecT-assisted CRISPR–Cas9 approach | Easy insertion or deletion of genomic DNA within less time |
|
|
| CRISPR-Cas system + ssDNA recombineering | A plasmid-encoded template, oligonucleotide donor and an inducible DNA recombinase |
|
|
|
| Genome modification of |
|
|
| CRISPR interference (CRISPRi) systems | CRISPRi with catalytically dormant form of Cas9 (dCas9) for gene expression. Marker free | ( |
|
| Single-strand (ss) DNA recombineering | Mediates chromosomal incorporation of mutation. Antibiotic selection free (0.4%–16% efficiency) | ( |
|
| λ-Red-like recombinase system, a (Ds) DNA recombineering | A site-specific recombinase system for precise deletion and replacement with high efficiency |
|
|
| λ-Red-like recombinase system, a (Ds) DNA recombineering | For deletion and insertion of Gfp gene. marker free |
|
Application of Pediococcus in health-related conditions.
| Disorder/disease | Organism/strain | Characteristics | References |
|---|---|---|---|
| Oxidative stress |
| ZJUAF-4 administration improved Nrf2 expression and its downstream genes, preserved activity of the intestinal. Exerts antioxidant potential |
|
| Colitis |
| Incredibly preserved intestinal membrane integrity, modulates the immunological profiles, gut microbiota, and metabolite content |
|
| Biosorption of heavy metal |
| Good human gastrointestinal system tolerance properties, reduced Cd bioaccessibility, and protection against Cr toxicity | ( |
| Shields brush border membrane effect |
| Improved fecal evacuation of cadmium with a reduced tissue deposition effect, decreased hyperplasia, reduced invasion of lymphocytes, and enhancement of BBM-based disaccharidases |
|
| Aging |
| Improved collagen in UVB-irradiated human skin fibroblasts | (Ji Hoon et al., 2019) |
| Melanogenesis |
| Reduced overproduction and accumulation of melanin that induces skin darkening and abnormalities | (Sukyung et al., 2020) |
| Intestinal inflammation |
|
|
|
|
|
Summaries of available therapeutics from various recombinant LAB.
| Strains | Therapeutic products | Health-related condition | References |
|---|---|---|---|
|
| Interleukin-10, proinsulin | Diabetes mellitus (Type I) |
|
|
| Interleukin-12 | Asthma |
|
|
| HSP65–6P277 | Diabetes mellitus (Type I) |
|
|
| Kisspeptin | Colorectal cancer |
|
|
| HPV-16-E7 | Human papillomavirus 16-induced cancers | ( |
|
| Interleukin-6 | Adjuvant |
|
|
| Peanut allergen Ara2 | Hypersensitivity intolerance (Type I) |
|
|
| Birch allergen Betv1 | Hypersensitivity intolerance (Type I) |
|
|
| Glycosylated tyrosinase-related protein-2 | Skin cancer |
|
|
| Japanese cedar pollen allergen Cry j1 | Hypersensitivity intolerance (Type I) |
|
|
| γ-Amino butyric acid | Anxiety, hypertension |
|
|
| Hyaluronic acid | Dermatitis, wound healing |
|